Clinical Trial

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-24.
Status change: Not Yet Recruiting → Recruiting 2026-01-05
Trial Details
NCT Number NCT07002177
Lead Sponsor Forward Pharmaceuticals Co., Ltd.
Conditions Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Locally Advanced Breast Cancer (LABC), ER+ Breast Cancer
Enrollment 196 participants
Start Date 2025-06-01
Primary Completion 2028-05-01 (estimated)
Study Completion 2028-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-07